Arks gains NHS reimbursement for KerraMax dressing
This article was originally published in Clinica
Ark Therapeutics has gained reimbursement approval from the UK’s National Health Service (NHS) for its KerraMax absorbent dressing. KerraMax, which is expected to make its market debut on November 1, is used for the management of leg ulcers. The London-based firm said that managing and treating venous leg ulcers is estimated to cost the NHS up to £300m ($510m) each year, with the UK market for existing absorbent dressings valued at approximately £10m. Ark also recently received NHS reimbursement approval for its Neuropad test for peripheral autonomic neuropathy in the feet of diabetic patients (see Clinica No 1325 p 21).
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals